Insider trade

Tango Therapeutics (TNGX): Director sold ~$80K

John B Ketchum, Director at Tango Therapeutics, sold ~$80K of Tango Therapeutics shares.

~$80K
Approx. value · 3,333 sh @ $24.08
22K
Holds after · shares reported
Traded
Nov 17, 2026
Filed
Nov 19, 2026

What stands out in this filing

  • The sale was 13.4% of the shares this insider held before it; the filing reports 21,604 shares afterwards.
  • 3,333 shares at an average of $24.08 each, as reported on the form.
  • Footnote references a pre-arranged trading plan (Rule 10b5-1).

Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Oct 1, 2026Insider · 1 personInsiders: 2 sales (~$661K)
  2. Nov 2, 2026Insider · 2 peopleInsiders: 4 sales (~$270K)
  3. Nov 6, 20265% stakeFMR LLC reported a passive stake (13G) of 15.0%
  4. Nov 9, 2026Company filing · Form 8-K · ResultsReported its results
  5. Nov 11, 2026InsiderOfficer sold ~$125K of TNGX shares in the open market
  6. Nov 16, 20265% stakeTCG Crossover GP II, LLC reported a passive stake (13G) of 4.6%
  7. Nov 16, 20265% stakeFarallon Capital Management, L.L.C. reported a passive stake (13G) of 4.9%
  8. Nov 17, 2026 · this disclosureInsiderDirector sold ~$80K of TNGX shares in the open market
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Tango Therapeutics

For Tango Therapeutics, OQRO holds 10 insider filings (SEC Form 4 or Form 144) and 2 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its TNGX page.

How this filing works

Explore the data

Common questions

Which Tango Therapeutics (TNGX) insider traded, and how much?

John B Ketchum, Director at Tango Therapeutics, sold ~$80K of Tango Therapeutics shares. 3,333 shares at $24.08.

When did it happen, and when was it made public?

Traded: Nov 17, 2026. Filed: Nov 19, 2026. That is 2 days between the two dates.

What stands out in this filing?

The sale was 13.4% of the shares this insider held before it; the filing reports 21,604 shares afterwards. 3,333 shares at an average of $24.08 each, as reported on the form. Footnote references a pre-arranged trading plan (Rule 10b5-1).

Is the dollar amount exact?

It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.

Where does this information come from?

From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Tango Therapeutics recently?

For Tango Therapeutics, OQRO holds 10 insider filings (SEC Form 4 or Form 144) and 2 fund holdings reports (13F) dated in the last 90 days. They are listed on the TNGX page.

Does this mean TNGX stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Tango Therapeutics

Everything OQRO holds on this company is on its TNGX page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data